Literature DB >> 16267134

An improved reverse genetics system for influenza A virus generation and its implications for vaccine production.

Gabriele Neumann1, Ken Fujii, Yoichiro Kino, Yoshihiro Kawaoka.   

Abstract

The generation of vaccines for highly pathogenic avian influenza viruses, including those of the H5N1 subtype, relies on reverse genetics, which allows the production of influenza viruses from cloned cDNA. In the future, reverse genetics will likely be the method of choice for the generation of conventional influenza vaccine strains because gene reassortment by more traditional methods is cumbersome. Established systems for the artificial generation of influenza A viruses require transfection of cells with the eight to 12 plasmids that provide the eight influenza viral RNAs as well as the polymerase and nucleoproteins of the virus. However, cell lines appropriate for human vaccine production (e.g., Vero cells) cannot be transfected with high efficiencies. To overcome these problems, we established a reverse genetics system in which the eight RNA polymerase I transcription cassettes for viral RNA synthesis are combined on one plasmid. Similarly, two cassettes encoding the hemagglutinin and neuraminidase segments and six cassettes encoding the remaining proteins were combined. We also combined three RNA polymerase II transcription cassettes for the expression of the polymerase subunits. By combining these cassettes, we reduced the number of plasmids required for virus generation significantly and produced influenza A virus in Vero cells with higher efficiency than with the traditional 12 plasmid system. This new system is thus suitable for influenza virus vaccine production and may be applicable to other reverse genetics systems that rely on the introduction of several plasmids into eukaryotic cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16267134      PMCID: PMC1283806          DOI: 10.1073/pnas.0505587102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Development of Vero cell-derived inactivated Japanese encephalitis vaccine.

Authors:  Keishin Sugawara; Kiyoto Nishiyama; Yuji Ishikawa; Motoharu Abe; Kengo Sonoda; Kazuhiro Komatsu; Yoshikane Horikawa; Kengo Takeda; Tomitaka Honda; Shoji Kuzuhara; Yoichiro Kino; Hiroshi Mizokami; Kyosuke Mizuno; Tetsuya Oka; Kennosuke Honda
Journal:  Biologicals       Date:  2002-12       Impact factor: 1.856

2.  Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children.

Authors:  Scott A Halperin; Bruce Smith; Taoufik Mabrouk; Marc Germain; Pierre Trépanier; Thomas Hassell; John Treanor; Richard Gauthier; Elaine L Mills
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

3.  The annual production cycle for influenza vaccine.

Authors:  Catherine Gerdil
Journal:  Vaccine       Date:  2003-05-01       Impact factor: 3.641

4.  Humoral and cell-mediated immunity to vero cell-derived influenza vaccine.

Authors:  P Brühl; A Kerschbaum; O Kistner; N Barrett; F Dorner; M Gerencer
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

5.  Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system.

Authors:  Carolyn Nicolson; Diane Major; John M Wood; James S Robertson
Journal:  Vaccine       Date:  2005-04-22       Impact factor: 3.641

6.  Rescue of influenza B virus from eight plasmids.

Authors:  Erich Hoffmann; Kutubuddin Mahmood; Chin-Fen Yang; Robert G Webster; Harry B Greenberg; George Kemble
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-09       Impact factor: 11.205

7.  Mortality associated with influenza and respiratory syncytial virus in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

8.  Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics.

Authors:  Hiroichi Ozaki; Elena A Govorkova; Chenghong Li; Xiaoping Xiong; Robert G Webster; Richard J Webby
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome.

Authors:  Ron A M Fouchier; Peter M Schneeberger; Frans W Rozendaal; Jan M Broekman; Stiena A G Kemink; Vincent Munster; Thijs Kuiken; Guus F Rimmelzwaan; Martin Schutten; Gerard J J Van Doornum; Guus Koch; Arnold Bosman; Marion Koopmans; Albert D M E Osterhaus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

10.  Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.

Authors:  Kanta Subbarao; Hualan Chen; David Swayne; Louise Mingay; Ervin Fodor; George Brownlee; Xiyan Xu; Xiuhua Lu; Jacqueline Katz; Nancy Cox; Yumiko Matsuoka
Journal:  Virology       Date:  2003-01-05       Impact factor: 3.616

View more
  67 in total

1.  Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts.

Authors:  Boris Ferko; Christian Kittel; Julia Romanova; Sabine Sereinig; Hermann Katinger; Andrej Egorov
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

2.  Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.

Authors:  Shixia Wang; Jessica Taaffe; Christopher Parker; Alicia Solórzano; Hong Cao; Adolfo García-Sastre; Shan Lu
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

3.  An adenovirus vector-mediated reverse genetics system for influenza A virus generation.

Authors:  Makoto Ozawa; Hideo Goto; Taisuke Horimoto; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

4.  An inhibitory activity in human cells restricts the function of an avian-like influenza virus polymerase.

Authors:  Andrew Mehle; Jennifer A Doudna
Journal:  Cell Host Microbe       Date:  2008-08-14       Impact factor: 21.023

Review 5.  Traditional and new influenza vaccines.

Authors:  Sook-San Wong; Richard J Webby
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

6.  Highly sensitive real-time in vivo imaging of an influenza reporter virus reveals dynamics of replication and spread.

Authors:  Vy Tran; Lindsey A Moser; Daniel S Poole; Andrew Mehle
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

7.  Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza.

Authors:  John Steel; Anice C Lowen; Lindomar Pena; Matthew Angel; Alicia Solórzano; Randy Albrecht; Daniel R Perez; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

8.  Alternative reverse genetics system for influenza viruses based on a synthesized swine 45S rRNA promoter.

Authors:  Kai Wang; Qi Huang; Zhiwei Yang; Kezong Qi; Hongmei Liu; Hongjun Chen
Journal:  Virus Genes       Date:  2017-04-22       Impact factor: 2.332

9.  Mitigation approaches to combat the flu pandemic.

Authors:  Raman Chawla; Rakesh Kumar Sharma; Deepali Madaan; Neha Dubey; Rajesh Arora; Rajeev Goel; Shefali Singh; Vinod Kaushik; Pankaj Kumar Singh; Vivek Chabbra; Janak Raj Bhardwaj
Journal:  J Glob Infect Dis       Date:  2009-07

10.  Improved and simplified recombineering approach for influenza virus reverse genetics.

Authors:  Qinfang Liu; Shuai Wang; Guangpeng Ma; Juan Pu; Nicole E Forbes; Earl G Brown; Jin-Hua Liu
Journal:  J Mol Genet Med       Date:  2009-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.